Position in CDXS
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$39,522
-$18,328 QoQ
Shares Held
24,247
-31.7% QoQ
Ownership
0.027%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in CDXS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026INTECH INVESTMENT MANAGEMENT LLC holds $187,195,319 across 175 Biotechnology names. CDXS ranks #159 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
68,009 | $22,502,137 | |
| 2 | EXEL |
Exelixis, Inc.
|
401,748 | $17,230,971 | |
| 3 | INCY |
Incyte Corp
|
136,704 | $12,866,580 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
162,864 | $10,525,900 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
19,713 | $8,802,642 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,319 | $7,200,231 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
34,379 | $6,499,349 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
55,949 | $3,811,805 |
All Filings in CDXS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $39,522 | 24,247 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $57,850 | 35,491 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $100,120 | 41,033 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $118,083 | 48,395 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $173,464 | 64,485 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $157,939 | 33,111 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $65,770 | 21,354 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||